The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the ...

Bausch + Lomb, which is listed on both the Toronto and New York stock exchanges, said full separation remains the goal, and that it continues to operate as its own entity. Bausch Health said it would ...

Bausch Health failed to agree a deal to sell its Bausch + Lomb eyecare subsidiary but remains focused on a separation. Bausch + Lomb said Thursday talks held with potential buyers won't result in a ...

(Reuters) -Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday, sending its ...

Bausch Health Companies (BHC) issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (BLCO), which was ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a price ...

Bausch & Lomb (NYSE:BLCO) fell 5.6% in premarket trading after ending a sales process without finding a buyer. “Taking Bausch + Lomb private with a third-party buyer was one of several options being ...

Shares in ophthalmology specialist Bausch + Lomb (B+L) have lost almost 10% of their value on a report that a joint takeover bid for the group is in trouble. The Financial Times has said that ...

Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long effort to tackle some of its approximately $20 billion dollars of debt and ...